sb 202190 has been researched along with Cancer of Endometrium in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Excerpt | Relevance | Reference |
|---|---|---|
| "Endometrial carcinoma is the most common neoplasm of the female genital tract, accounting for nearly one half of all gynecologic cancers in the Western world." | 1.35 | Gonadotropin-releasing hormone (GnRH)-I and GnRH-II induce cell growth inhibition in human endometrial cancer cells: involvement of integrin beta3 and focal adhesion kinase. ( Choi, KC; Leung, PC; MacCalman, CD; Park, DW, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, DW | 1 |
| Choi, KC | 1 |
| MacCalman, CD | 1 |
| Leung, PC | 1 |
1 other study available for sb 202190 and Cancer of Endometrium
| Article | Year |
|---|---|
Gonadotropin-releasing hormone (GnRH)-I and GnRH-II induce cell growth inhibition in human endometrial cancer cells: involvement of integrin beta3 and focal adhesion kinase.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endometri | 2009 |